Vericel (VCEL) Long-Term Investments (2019 - 2026)
Vericel recorded quarterly Long-Term Investments of $101.3 million in Q1 2026, up 65.0% quarter-over-quarter from $61.4 million in Q4 2025, and up 22.34% year-over-year from $82.8 million in Q1 2025.
Vericel's Long-Term Investments history runs 8 years deep, the most recent figure standing at $101.3 million for Q1 2026.
- In Q1 2026, Long-Term Investments rose 22.34% year-over-year to $101.3 million; the TTM figure through Mar 2026 stood at $101.3 million (up 22.34% YoY), while the FY2025 annual figure was $61.4 million, up 53.95% from the prior year.
- Long-Term Investments came in at $101.3 million for Q1 2026 at Vericel, up from $61.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $101.3 million in Q1 2026 to a low of $20.0 million in Q4 2022.
- A 5-year average of $52.1 million and a median of $49.7 million in 2025 frame the typical range for Long-Term Investments.
- Across the five-year window, Long-Term Investments tumbled 70.03% in 2023 and surged 299.88% in 2024, its largest moves.
- Vericel's Long-Term Investments stood at $20.0 million in 2022, then rose by 26.66% to $25.3 million in 2023, then surged by 57.73% to $39.9 million in 2024, then surged by 53.95% to $61.4 million in 2025, then soared by 65.0% to $101.3 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $101.3 million, $61.4 million, and $49.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | 101.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.30 Mn |
| Dec 31, 2025 | 61.40 Mn |
| Sep 30, 2025 | 49.66 Mn |
| Jun 30, 2025 | 47.40 Mn |
| Mar 31, 2025 | 82.80 Mn |
| Dec 31, 2024 | 39.88 Mn |
| Sep 30, 2024 | 80.90 Mn |
| Jun 30, 2024 | 26.12 Mn |
| Mar 31, 2024 | 29.43 Mn |
| Dec 31, 2023 | 25.28 Mn |
| Sep 30, 2023 | 20.23 Mn |
| Jun 30, 2023 | 20.99 Mn |
| Mar 31, 2023 | 77.40 Mn |
| Dec 31, 2022 | 19.96 Mn |
| Sep 30, 2022 | 67.50 Mn |
| Jun 30, 2022 | 68.40 Mn |
| Mar 31, 2022 | 67.70 Mn |
| Dec 31, 2021 | 25.69 Mn |
| Sep 30, 2021 | 20.24 Mn |
| Jun 30, 2021 | 24.83 Mn |
| Mar 31, 2021 | 51.40 Mn |
| Dec 31, 2020 | 24.10 Mn |
| Jun 30, 2020 | 25.10 Mn |
| Mar 31, 2020 | 37.70 Mn |
| Dec 31, 2019 | 9.25 Mn |